- $445.91m
- $387.58m
- $180.46m
Brief: Kamada Reports Q1 Loss Of 4 Cents Per Share
Brief: Kamada Announces Expansion Of Pivotal Phase 3 Clinical Trial Of Inhaled AAT
Brief: Kamada Reports Fiscal Year, Fourth Quarter 2021 Financial Results
Brief: Kamada Announces Strategic Transformational Transaction
Brief: Kamada Reports Q3 Loss Of 2 Cents Per Share
Brief: Kamada Reports Second Quarter And First Half 2021 Financial Results
Brief: Kedrion And Kamada Announce FDA Approval Of Kedrab® Label Update, Confirming Safety And Effectiveness In Children
Brief: Kamada Reports Q1 Revenue Of $24.9 Mln
Brief: Kamada Announces Amendment To Glassia License Agreement With Takeda
Brief: Kamada Announces Top-Line Results From Phase 1/2 Trial Of Its Plasma-Derived Hyperimmune Globulin Treatment For Covid-19
Kamada: Falls after Q4 disappoints
Brief: Kamada Posts Q4 Earnings Per Share $0.04
Brief: Kamada Acquires FDA-Licensed Plasma Collection Center From Blood And Plasma Research Inc In Texas
Kamada: Rises on distribution deals for three biosimilars
Potential Collective Maximum Sales Of Three Products In Israeli Market Is Estimated At $5-$7 Million Annually
Has Been Selected For Addition To Nasdaq Biotechnology Index
Brief: Kamada To Announce Receipt Of A Notice Of Labor Dispute From Employee's Committee
Brief: Kamada Reports Third Quarter And First Nine Months Of 2020 Financial Results, Recent Achievements And Corporate Development
Kamada: Rises on supply deal with Israel for experimental COVID-19 treatment